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EDITORIAL
Transforming Translation: Impact of
Clinical and Translational Science
JA Wagner1,∗ and DL Kroetz2
What is translational medicine? This question has been vigor-
ously debated by various constituencies for many years. One
recent, encompassing definition of translational medicine
was developed for the Strategic Plan in service of the Amer-
ican Society for Clinical Pharmacology and Therapeutics
(ASCPT).1,2 Not coincidentally, the ASCPT Strategic Plan was
aptly entitled “Transforming Translation.”
“Implementation of the ASCPT Strategic Plan will be
guided by a broad and inclusive description of transla-
tional medicine to reflect the diversity of scientific disci-
plines involved in translational research within our Society.
For the purpose of this document, translational research,
translational science, and translational medicine will be
used interchangeably with a unifying principle that the ulti-
mate purpose is to improve human health via a “bench to
bedside” approach. There are many definitions of transla-
tional medicine as well as translational science and transla-
tional research, which provide context for ASCPT’s efforts.
John Hutton3 defines translational research as “Research
[that] transforms scientific discoveries arising from labora-
tory, clinical or population studies into new clinical tools
and applications that improve human health by reduc-
ing disease incidence, morbidity, and mortality.” Another
perspective4 is “Translational research fosters the multi-
directional integration of basic research, patient-oriented
research, and population-based research, with the long-
term aim of improving the health of the public.”
From ASCPT’s perspective, translational medicine is a mul-
tifaceted discipline with a focus on translational thera-
peutics. In a broad sense, translational medicine bridges
across the discovery, development, regulation, and utiliza-
tion spectrum. It may include application of research find-
ings from genes, proteins, cells, tissues, organs, and ani-
mals, to clinical research in patient populations, all aimed at
optimizing and predicting outcomes in specific patients. For
clinical pharmacology, the focus of translational research is
on the discovery, development, regulation, and use of phar-
macologic agents to improve clinical outcome and inform
optimal use of therapeutics in patients. In addition, transla-
tional research in clinical pharmacology may include eval-
uation of various biomarkers of pharmacologic response
and assessing the linkage between biomarker response and
clinical endpoints in patients. Our broad description also
includes how the response to a therapeutic intervention in a
particular disease may translate to a response in another
disease, as well as translation of safety signals across
species and/or patient populations. Translational research
is bolstered by quantitative, model-based, and mechanistic
understanding of disease biology and pharmacology. Con-
sequently, core disciplines, including clinical pharmacol-
ogy, pharmacogenomics, systems pharmacology, precision
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medicine, as well as others play an integral role in enabling
translational research and translational medicine.”1
Published research on translational medicine, translational
science, and translational research has exploded, with over
7,000 PubMed citations in the last year alone (Figure 1), and
yet the cross-therapeutic needs of the translational medicine
community remain underserved. As described by Rocci2 in
this issue, one important intent of the ASCPT Strategic Plan
is to “transform translation” and focus the attention of the
Society on translational research. Thus, a major aim of Clini-
cal and Translational Science (CTS), now under the auspices
of ASCPT, is to be a beacon and organizing principle for the
field of translational medicine. The broad definition devel-
oped by ASCPT for translational medicine serves as a goal
post for the focus of CTS. With this definition in mind, the
journal highlights original research that helps bridge labora-
tory discovery with the diagnosis and treatment of human
disease. Publications may appear as full Articles, Commen-
taries, Phase Forward (well-conducted, concisely reported,
and relevant clinical trials), Reviews, or Tutorials. CTS also
includes invited didactic content that covers the connections
between clinical pharmacology and translational medicine.
These additional features provide context for research arti-
cles and facilitate understanding for a wide array of individu-
als interested in clinical and translational science. CTS wel-
comes high quality, scientifically sound original manuscripts
focused on clinical pharmacology and translational science,
including animal, in vitro, in silico, and clinical studies sup-
porting the breadth of drug discovery, development, regula-
tion, and clinical use of drugs. Example topics of interest are
displayed in Table 1.
Biomarkers have an enormously important role in the
definition of translational medicine and serve as the com-
mon language of translational sciences. A biomarker has
been defined as “a characteristic that is objectively mea-
sured and evaluated as an indicator of normal biologic pro-
cesses, pathogenic process, or pharmacologic responses
to a therapeutic intervention.”5 This comprehensive defi-
nition of biomarkers arose from the April 1999 US Food
and Drug Administration (FDA)/National Institutes of Health
(NIH) consensus conference on “Biomarkers and Surrogate
Endpoints: Advancing Clinical Research and Applications,”
and emphasized that biomarkers are medical measure-
ments, including physiological measurements, blood tests,
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Figure 1 Translational medicine, translational science, and translational research publishing has grown dramatically over the last decade.
Increase in publications identified by the key words “translational medicine” [or] “translational science” [or] “translational research” in
PubMed in 2006 through 2015 and plotted by year.
Table 1 Example topics of interest for Clinical and Translational Science
Translational medicine, including studies focused on interrogation/evaluation
of mechanism-of-action, human physiology, and interruption of disease
pathophysiology
Hypothesis generating nonclinical and clinical studies, including small clinical
trials
Models of human disease and their therapeutic implications
Studies that guide Phase 2 dose selection
Studies that identify or support biomarkers that can be used at any stage of
drug development
Studies that demonstrate effective communication between basic and clinical
science
Regulatory and public health policy implications of translational studies
Pharmacokinetic/pharmacodynamic (PK/PD) and quantitative pharmacology
as these relate to translational medicine
Precision medicine
molecular analyses of biopsies, genetic or metabolic data,
and measurements from images. Biomarkers serve as the
“glue” that adheres many of the component translational
disciplines together, and are undergoing a renaissance of
increased interest. In this issue Li et al.6 discuss the inno-
vative use of imaging as a biomarker in oncology. The uptick
in interest in the field of biomarkers include activities such as
US Congressional scrutiny (in the form of the 21st Century
Cures legislation), the FDA’s biomarker qualification pathway,
the FDA/NIH biomarker taxonomy effort, the Foundation for
the National Institutes of Health (FNIH) Biomarkers Consor-
tium, Brookings / FDA, efforts by Centers of Excellence in
Regulatory Science and Innovation, Critical Path Institute (C-
PATH), National Biomarkers Development Alliance, and the
Institute of Medicine (IOM) report on biomarkers and surro-
gate endpoints. The high level of community attention under-
lines the importance of biomarkers in translational medicine,
and the corresponding role biomarkers are expected to have
in CTS.
Another tenet of the ASCPT definition of translational
medicine is that translational research is bolstered by quanti-
tative, model-based, and mechanistic approaches. Sheiner’s
learn-confirm paradigm7 leads naturally to the idea of
translational medicine in which pharmacometric models of
drug efficacy and safety link preclinical and clinical data,
particularly biomarker information, with prior knowledge of
disease, and provide a quantitative approach to improving
drug development and decision-making, as well as trans-
lational medicine more generally. Pharmacometric models
contribute to successful and efficient drug development by
illuminating drivers of efficacy and safety outcomes, by pre-
dicting the outcome of future events using simulations of
alternative study designs and understudied patient pop-
ulations, and by estimating the probability of a success-
ful trial given a set of well-articulated assumptions. These
concepts culminate in the idea of model-based drug
development, wherein the sciences of pharmacokinetics,
pharmacodynamics, statistics, clinical pharmacology, and
therapeutic areas are integrated to drive more robust
decision-making. Key benefits of this approach include
quantitative integration of translational medicine knowledge
and discussion of important assumptions.
Pharmacogenomics is often considered the poster child
of translational medicine. Defined by the International Con-
ference of Harmonization as the “study of variations in DNA
sequences as related to drug response,” pharmacogenomics
has long been recognized for its contribution to interindivid-
ual variability in drug response and toxicity, and an increas-
ing number of drug labels include recommendations for
genotype-guided dosing of therapeutics.8,9 In recent years,
the focus of pharmacogenomics research has evolved from
the traditional emphasis on discovering genetic determinants
of drug exposure (pharmacokinetics), to a broader defini-
tion that includes genes and pathways that underlie the
pharmacologic and toxic response to therapeutics (phar-
macodynamics). In this issue, Khalil et al.10 and Hamadeh
et al.11 identify the impact of pharmacogenomics in new
populations. There remains a significant need for continued
efforts to implement current pharmacogenomics knowledge
into patient care. In addition, unbiased approaches using
genome-wide genotyping and sequencing are being imple-
mented to identify novel genes that contribute to therapeutic
efficacy and toxicity. Pharmacogenomic research holds
the promise of novel drug design targeting specific DNA
sequences and a molecular understanding of drug response
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and toxicity that can be incorporated into drug development
and therapeutic utilization. Translational medicine requires a
systems level understanding of variability in drug response
that considers genetic variation in the context of environ-
mental and other nongenomic influences. CTS welcomes
pharmacogenomics contributions that span the bench-to-
bedside spectrum of translational sciences.
One of the most innovative approaches to translational
medicine evolves the classic “bench-to-beside” approach to
“bedside-to-bench-to-bedside,”12 and, thus, integrates the
many facets of translational medicine. One recent, power-
ful example highlights the creative energy, innovation, inter-
play of cutting-edge technology, and benefit to patients of
this approach. In 2003, a mutation in proprotein convertase
subtilisin/kexin type 9 (PCSK9) was discovered and asso-
ciated with remarkably low cholesterol. This clinical obser-
vation drove interest in target validation that elucidated a
key role for PCSK9 binding low-density lipoprotein (LDL)
receptors, which in turn control LDL cholesterol levels in
the circulation. Human genetics prompted confirmation that
PCSK9 null mice also had remarkably low cholesterol. These
bedside-to-bench findings drove the search and discovery
of antibody inhibitors of PCSK9, which could reduce degra-
dation of LDL receptors resulting in lower cholesterol levels.
Twelve years after the initial bedside observations, two mon-
oclonal antibodies, alirocumab and evolocumab, have been
shown to dramatically reduce LDL cholesterol in patients
with hypercholesterolemia.13 Although statins have been
the mainstay of cholesterol-reducing therapy for decades,
PCSK9 monoclonal antibodies will now have an important
role in statin-intolerant and unresponsive patients, serving
this unmet medical need.
In addition to the important scientific components that
make up the field of translational medicine, there are societal
trends, including “democratization” of science and health
care, the explosion of social media in science and health
care, the increasing role of the patient, precompetitive col-
laboration, and the globalization of research. Exciting devel-
opments in translational medicine are occurring outside
the United States, which necessities a broad, international
approach including Europe, United States, Asia, and emerg-
ing economies. For example, China has seen double-digit
growth in its biotechnology industry and has gone from being
one of the slowest to one of the fastest nations in the adop-
tion of new biotechnologies. CTS intends to embrace these
societal trends as the field of translational medicine evolves.
Translational sciences research holds the promise of more
effective and safe therapeutics. Inherent in this promise is the
need for robust bench-to-bedside and bedside-to-bench-to-
bedside research that embraces the tremendous technolog-
ical advancements and advanced analysis methods that are
driving modern data-driven discoveries. Our vision for CTS is
that it will provide a widely recognized platform for the broad
dissemination of high quality translational science research
that will lead to the optimal use of therapeutics. We encour-
age submissions from the diverse fields that span the trans-
lational sciences spectrum across diverse therapeutic areas
and across the breadth of discovery, development, regula-
tion, and clinical use of therapeutics.
Acknowledgments. We gratefully acknowledge the compelling
work done by the members of the 2015–2020 ASCPT Strategic Planning
Task Force who developed the plan: Richard Lalonde, PharmD,Chair; John
A. Wagner, MD, PhD, President; Antoinette Ajavon, PhD; Kathleen M. Gia-
comini, PhD; Dan Hartman, MD; Anne C. Heatherington, PhD; Sean Hen-
nessy, PharmD, PhD; Julie A. Johnson, PharmD; Lang Li, PhD; Donald E.
Mager, PharmD, PhD; Min Soo Park, MD, PhD; Kellie Schoolar Reynolds,
PharmD; Mario L. Rocci, Jr., PhD; Michelle A. Rudek, PharmD, PhD; Vir-
ginia (Ginny) D. Schmith, PhD, FCP; Valentina Shakhnovich, MD; Aubrey
Stoch, MD; Pieter H. van der Graaf, PhD, PharmD; Satsuki Yamada, MD,
PhD; with support from ASCPT staff Sharon J. Swan, FASAE, CAE; Elise
Laffman-Johnson; Megan McBeath Hay; and Lisa Williamson. Addition-
ally, we thank the CTS Associate Editors for all the activities leading to
the relaunch of the journal: Mark Dresser, PhD; Naoto Uemura, MD, PhD;
Nina Isoherranen, PhD; Michael A. Pacanowski, PharmD, MPH; Sarah M.
Robertson, PharmD; and Valentina Shakhnovich, MD. Finally, thanks to
the outstanding managing editorial team: Elise Laffman-Johnson, Emma
Shumeyko, and Rachel Taylor.
Conflict of Interest/Disclosure. J.A.W. is an employee of Takeda
Pharmaceutical International Co. and may potentially own stock and/or
hold stock options in the Company. D.L.K. has no conflicts to disclose.
1. American Society for Clinical Pharmacology and Therapeutics. ASCPT Strategic
Plan: Transforming Translation http://www.ascpt.org/portals/8/strategicplan/index.html
(2015).**
2. Rocci, M.L. Jr. The American Society for Clinical Pharmacology and Therapeutics
(ASCPT) – a rich heritage en route to an exciting future. Clin. Transl. Sci. 9: 6–8 (2016).
3. Wang, X. A new vision of definition, commentary, and understanding in clinical and trans-
lational medicine. Clin. Transl. Med. 1: 5 (2012).
4. Rubio, D.M. et al. Defining translational research: implications for training. Acad. Med.
85: 470–475 (2010).
5. NIH Definitions Working Group. Biomarkers and surrogate endpoints in clinical research:
definitions and conceptual model. In Biomarkers and Surrogate Endpoints: Clinical
Research and Applications (ed. Downing, G.L.) 1–9 (Elsevier, Amsterdam, 2000).
6. Li, C.H. et al. Comparative effects of CT imaging measurement on RECIST endpoints and
tumor growth kinetics modelling. Clin. Transl. Sci. 9: 43–50 (2016).
7. Sheiner, L.B. Learning versus confirming in clinical drug development. Clin. Pharmacol.
Ther. 61: 275–291 (1997).
8. Ehmann, F., Caneva, L. & Papaluca M. European Medicines Agency initiatives and per-
spectives on pharmacogenomics. Br. J. Clin. Pharmacol. 77: 612–617 (2014).
9. Yip, V.L., Hawcutt, D.B. & Pirmohamed,M. Pharmacogenetic Markers of Drug Efficacy and
Toxicity. Clin. Pharmacol. Ther. 9861–9870 (2015).
10. Khalil, B.M. et al. Genetic and nongenetic factors affecting clopidogrel response in the
egyptian population. Clin. Transl. Sci. 9: 23–28 (2016).
11. Hamadeh, I.S. et al. Impact of GGCX, STX1B and FPGS polymorphisms on warfarin dose
requirements in European Americans and Egyptians. Clin. Transl. Sci. 9: 36–42 (2016).
12. Recke, A.& Ludwig, R.J. From bedside to bench–reverse translational medicine. Scientific
lessons from revertant mosaicism in ‘knockout’ humans. Exp. Dermatol. 23(8): 549–550
(2014).
13. Everett, B.M., Smith, R.J. & Hiatt, W.R. Reducing LDL with PCSK9 inhibitors–the clinical
benefit of lipid drugs. N. Engl. J. Med. 373: 1588–1591 (2015).
**[Correction added on 8 February 2016, after first online
publication: Reference 1 of the paper was updated]
C© 2015 The Authors. Clinical and Translational Science
published by Wiley Periodicals, Inc. on behalf of Ameri-
can Society for Clinical Pharmacology and Therapeutics.
This is an open access article under the terms of the Cre-
ative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided
the original work is properly cited.
www.wileyonlinelibrary/cts
